Nastech Pharmaceutical News (NASDAQ:NSTK)
| Latest Nastech Pharmaceutical News Headlines | | Date | Time | Source | | | 02/29/2008 | 2:23PM | PRNUS | Nastech Pharmaceutical Company Inc. to Hold Conference Call to Discuss Corporate Restructuring and Future Strategy on Monday, Ma
BOTHELL, Wash., Feb. 29 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical Company Inc. (NASDAQ:NSTK) announced today that it will host a conference call with investors and security analysts on Monday, March 3, 2008, at 11:30 a.m. Eastern time (8:30 a.m. Pacific time) to discuss the Company's corporate restructuring initiatives... More...>> |
| 02/12/2008 | 2:05PM | PRNUS | Nastech Pharmaceutical Company Implements Additional Workforce Reduction as Part of Previously Announced Corporate Restructuring
BOTHELL, Wash., Feb. 12 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical Company Inc. (NASDAQ:NSTK) announced today that its Board of Directors has approved a plan to further reduce operating expenses and align the company's workforce with its strategic, business and clinical development requirements.
"The workforce... More...>> |
| 02/05/2008 | 8:00AM | PRNUS | Nastech Appoints MDRNA, Inc. Directors Strategic Advisory Board
BOTHELL, Wash., Feb. 5 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical Company Inc. ("Nastech") (NASDAQ:NSTK) announced today that it has named members to the MDRNA, Inc. ("MDRNA") Directors Strategic Advisory Board that will provide scientific, financial and corporate governance expertise as Nastech moves to establish... More...>> |
| 01/08/2008 | 8:00AM | PRNUS | Nastech Completes Enrollment of Phase 2 Clinical Trial of PYY3-36 Nasal Spray to Treat Obesity
BOTHELL, Wash., Jan. 8 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical Company Inc. (NASDAQ:NSTK) announced the completion of enrollment for its Phase 2 clinical trial of PYY3-36 Nasal Spray to treat obesity. The Company enrolled 551 obese patients at multiple clinical sites in the United States for a six-month, randomized... More...>> |
| 01/08/2008 | 7:30AM | PRNUS | Nastech Receives Notice of Allowance for U.S. Patent Related to Methods for Identifying Cell-Specific Targeting Peptides
BOTHELL, Wash., Jan. 8 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical Company Inc. (NASDAQ:NSTK) announced today that the U.S. Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. patent application No. 10/976,942, entitled "Phage Displayed Trp Cage Ligands." The patent application has claims... More...>> |
| 01/07/2008 | 8:00AM | PRNUS | Nastech Appoints Bruce R. York as Interim Chief Financial Officer
BOTHELL, Wash., Jan. 7 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical Company Inc. (NASDAQ:NSTK) announced the appointment of Bruce R. York to the position of Secretary and interim Chief Financial Officer, effective January 4, 2008. Mr. York will replace Philip C. Ranker, who resigned as Chief Financial Officer and... More...>> |
| 12/20/2007 | 8:30AM | PRNUS | Nastech Announces Promotion of Gordon Brandt, M.D. to President
BOTHELL, Wash., Dec. 20 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical Company Inc. (NASDAQ:NSTK) announced today that it has promoted Gordon Brandt, M.D. to President of Nastech. Dr. Brandt previously held the title of Executive Vice President, Clinical Research and Medical Affairs. Dr. Steven Quay will remain the... More...>> |
| 12/18/2007 | 8:30AM | PRNUS | Nastech Assigns Intellectual Property Related to the Development of RNA-Based Therapeutics to its Subsidiary, MDRNA, Inc.
Assignment of over 100 RNA-related Inventions a Key Step in Establishing MDRNA as an Independent Company
BOTHELL, Wash., Dec. 18 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical Company Inc. ("Nastech") (NASDAQ:NSTK) announced today that it has assigned (i) certain Nastech licenses to third-party intellectual property... More...>> |
| 12/05/2007 | 7:45AM | PRNUS | Nastech Enters Into Feasibility Study to Develop a Non-Injectable Dosage Form of Factor IX to Control Bleeding
BOTHELL, Wash., Dec. 5 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical Company Inc. (NASDAQ:NSTK) announced today that they have entered into a feasibility study with an undisclosed global leader in the production of plasma products, to develop an alternative dosage form of Factor IX protein which is currently administered... More...>> |
| 11/27/2007 | 11:15AM | PRNUS | Nastech to Present at BMO Capital Markets Focus on Healthcare Conference
BOTHELL, Wash., Nov. 27 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical Company Inc. (NASDAQ:NSTK) announced today that it will present at the BMO Capital Markets Focus on Healthcare Conference on Wednesday, December 5, 2007 at 2:00 p.m. Eastern Time at the Millennium Broadway Hotel in New York City.
To access the... More...>> |
| 11/13/2007 | 5:48PM | PRNUS | Nastech Pharmaceutical Company Initiates Plan for Corporate Restructuring and Will Concentrate on Phase 2 Clinical Programs
Company to Host Webcast and Conference Call
BOTHELL, Wash., Nov. 13 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical Company Inc. ("Nastech") (NASDAQ:NSTK) announced today its corporate restructuring initiatives aimed at reducing operating expenses and enhancing shareholder value. Nastech will seek to establish its... More...>> |
| 11/13/2007 | 5:40PM | PRNUS | Nastech to Establish Subsidiary, MDRNA, Inc., as an Independent Company to Focus on the Development of RNA-Based Therapeutics
BOTHELL, Wash., Nov. 13 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical Company Inc. ("Nastech") (NASDAQ:NSTK) announced today that the Board of Directors has approved the recommendation of its Special Committee to move forward with the process of establishing Nastech's wholly-owned subsidiary, MDRNA, Inc. ("MDRNA... More...>> |
| 11/07/2007 | 7:15AM | PRNUS | Nastech Reacquires Teriparatide (Parathyroid Hormone; PTH1-34) Nasal Spray from Procter & Gamble
Company Will Advance Product into Phase 2 Bone Mineral Density Study in 1Q08
BOTHELL, Wash., Nov. 7 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical Company Inc. (NASDAQ:NSTK) announced today that it has reacquired the rights to teriparatide (Parathyroid Hormone; PTH1-34) nasal spray for the treatment of osteoporosis... More...>> |
| 10/31/2007 | 4:30PM | PRNUS | Nastech to Present at Acumen BioFin Rodman & Renshaw Healthcare Conference
BOTHELL, Wash., Oct. 31 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical Company Inc. (NASDAQ:NSTK) announced today that it will present at the Acumen BioFin Rodman & Renshaw Healthcare Conference on Monday, November 5, 2007 at 2:40 p.m. Eastern Time at the New York Palace Hotel in New York City.
To access the live... More...>> |
| 10/29/2007 | 4:05PM | PRNUS | Nastech Announces Third Quarter 2007 Financial Results
BOTHELL, Wash., Oct. 29 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical Company Inc. (NASDAQ:NSTK) today reported financial results for the three- and nine-month periods ended September 30, 2007.
Revenue for the quarter ended September 30, 2007 was $1.9 million, compared to $5.5 million for the quarter ended September... More...>> |
| 10/22/2007 | 4:30PM | PRNUS | Nastech to Release Third Quarter Financial Results and Host Webcast on Monday, October 29, 2007
BOTHELL, Wash., Oct. 22 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical Company Inc. (NASDAQ:NSTK) announced today that its third quarter financial results will be released on Monday, October 29, 2007. Management will host a conference call with investors and financial analysts to discuss these results and to provide... More...>> |
| 10/05/2007 | 9:00AM | PRNUS | Nastech Pharmaceutical Company Announces the Jeffrey Wenig Memorial Award for Outstanding Achievement in Drug Delivery
BOTHELL, Wash., Oct. 5 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical Company Inc. (NASDAQ:NSTK), a leader in molecular-biology based drug delivery technology, announced today the establishment of the Jeffrey Wenig Memorial Award for Outstanding Achievement in Drug Delivery, and its first recipients, Dr. Robert S... More...>> |
| 10/04/2007 | 9:00AM | PRNUS | Nastech Pharmaceutical Company Announces Promotion of Rick Costantino, Ph.D., to Chief Scientific Officer of Delivery
BOTHELL, Wash., Oct. 4 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical Company Inc. (NASDAQ:NSTK) announced today the promotion of Henry "Rick" Costantino, Ph.D., to Chief Scientific Officer of Delivery. Dr. Costantino will assume the responsibilities for leading Nastech's development of new drug delivery technologies... More...>> |
| 10/01/2007 | 2:45PM | PRNUS | Nastech Pharmaceutical Company Announces Initiation of Phase 2 Clinical Trial for PYY3-36 Nasal Spray to Treat Obesity
BOTHELL, Wash., Oct. 1 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical Company Inc. (NASDAQ:NSTK) announced today the start of a Phase 2 clinical trial evaluating the Company's PYY3-36 Nasal Spray in obese patients. The study will enroll approximately 500 obese patients for a six-month, randomized, placebo-controlled... More...>> |
| 09/26/2007 | 4:05PM | PRNUS | Nastech to Host 2007 Analyst and Institutional Investor Day
BOTHELL, Wash., Sept. 26 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical Company Inc. (NASDAQ:NSTK) will be hosting an analyst and institutional investor day in New York City on Thursday, October 4, 2007 from 12:00 p.m. - 3:00 p.m. Eastern Time at the Westin New York at Times Square, on 270 West 43rd Street. The luncheon... More...>> |
|
|
|